Ken Griffin Xtl Biopharmaceuticals LTD Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xtl Biopharmaceuticals LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 15,435 shares of XTLB stock, worth $37,661. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,435
Previous 13,631
13.23%
Holding current value
$37,661
Previous $38,000
2.63%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding XTLB
# of Institutions
6Shares Held
452KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$485,2860.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$485,2860.13% of portfolio
-
Morgan Stanley New York, NY33.2KShares$80,8880.0% of portfolio
-
Rhumbline Advisers Boston, MA5.58KShares$13,6240.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $13.3M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...